| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/23/2023 | -0.33% | B of A Securities | → $9 | Downgrades | Neutral → Underperform |
| 06/23/2023 | 21.82% | Barclays | → $11 | Downgrades | Equal-Weight → Underweight |
| 04/25/2023 | 21.82% | Barclays | $16 → $11 | Downgrades | Overweight → Equal-Weight |
| 04/24/2023 | 21.82% | Barclays | → $11 | Downgrades | Overweight → Equal-Weight |
| 02/28/2023 | 77.19% | Barclays | $15 → $16 | Maintains | Overweight |
| 02/17/2023 | 55.04% | BMO Capital | $16 → $14 | Downgrades | Outperform → Market Perform |
| 02/01/2023 | 66.11% | Barclays | $16 → $15 | Maintains | Overweight |
| 01/27/2023 | 66.11% | Jefferies | $13 → $15 | Upgrades | Hold → Buy |
| 11/15/2022 | 55.04% | JP Morgan | $13 → $14 | Maintains | Neutral |
| 11/10/2022 | 32.89% | UBS | $9 → $12 | Upgrades | Sell → Neutral |
| 11/08/2022 | 10.74% | Piper Sandler | → $10 | Upgrades | Underweight → Neutral |
| 10/25/2022 | 77.19% | Barclays | $21 → $16 | Maintains | Overweight |
| 10/21/2022 | 21.82% | Jefferies | → $11 | Initiates Coverage On | → Hold |
| 08/09/2022 | 77.19% | BMO Capital | $19 → $16 | Maintains | Outperform |
| 06/14/2022 | -0.33% | UBS | → $9 | Initiates Coverage On | → Sell |
| 05/12/2022 | 21.82% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 05/10/2022 | 10.74% | Piper Sandler | → $10 | Downgrades | Neutral → Underweight |
| 03/16/2022 | 10.74% | Piper Sandler | $17 → $10 | Maintains | Neutral |
| 03/10/2022 | 21.82% | Citigroup | $16 → $11 | Maintains | Neutral |
| 03/01/2022 | 43.96% | B of A Securities | $21 → $13 | Downgrades | Buy → Neutral |
| 03/01/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 06/15/2021 | 77.19% | Citigroup | → $16 | Initiates Coverage On | → Neutral |
| 03/10/2021 | 77.19% | Morgan Stanley | $18 → $16 | Maintains | Equal-Weight |
| 03/08/2021 | 66.11% | Goldman Sachs | $20 → $15 | Downgrades | Buy → Neutral |
| 03/02/2021 | 99.34% | JP Morgan | → $18 | Downgrades | Overweight → Neutral |
| 02/23/2021 | 110.41% | Raymond James | $23 → $19 | Maintains | Outperform |
| 01/25/2021 | 154.71% | Raymond James | $27 → $23 | Maintains | Outperform |
| 01/05/2021 | — | Argus Research | Initiates Coverage On | → Hold | |
| 12/14/2020 | 132.56% | Bernstein | → $21 | Initiates Coverage On | → Market Perform |
| 11/19/2020 | 143.63% | Goldman Sachs | → $22 | Reinstates | → Buy |
| 11/18/2020 | — | Edward Jones | Initiates Coverage On | → Sell |
What is the target price for Viatris (VTRS)?
The latest price target for Viatris (NASDAQ: VTRS) was reported by B of A Securities on October 23, 2023. The analyst firm set a price target for $9.00 expecting VTRS to fall to within 12 months (a possible -0.33% downside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Viatris (VTRS)?
The latest analyst rating for Viatris (NASDAQ: VTRS) was provided by B of A Securities, and Viatris downgraded their underperform rating.
When is the next analyst rating going to be posted or updated for Viatris (VTRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viatris, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viatris was filed on October 23, 2023 so you should expect the next rating to be made available sometime around October 23, 2024.
Is the Analyst Rating Viatris (VTRS) correct?
While ratings are subjective and will change, the latest Viatris (VTRS) rating was a downgraded with a price target of $0.00 to $9.00. The current price Viatris (VTRS) is trading at is $9.03, which is out of the analyst's predicted range.